News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.
Views & Analysis ASCO 2018 Preview – what to expect from this year’s conferen... pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.
News Merck shows canny cancer strategy in $5.76bn Eisai milestone... Firms will co-develop Lenvima and Keytruda combinations
News Eisai disappointed after NICE rejects earlier use for breast... NICE says no to Halaven in second line breast cancer
News NICE recommends funding for three thyroid cancer drugs Eisai's drug finally funded after two year delay
News NICE recommends Eisai's kidney cancer combination NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.